Avaleht › Äge müeloidne leukeemia › Minnesota

Äge müeloidne leukeemia kliinilised uuringud osariigis Minnesota

27 uuringut haiguse Äge müeloidne leukeemia jaoks otsivad osalejaid osariigis Minnesota.

Linnad osariigis Minnesota

Ametlik uuringutekst (inglise keeles)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Riverwood Healthcare Center, Aitkin
Mayo Clinic Health System in Albert Lea, Albert Lea
Essentia Health - Baxter Clinic, Baxter
ja veel 48

VärbamineVaatlusuuringTerved vabatahtlikud oodatud

Vanused 40–75 · Kõik sood · Uuendatud 2. okt 2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Mercy Hospital, Coon Rapids
Essentia Health - Deer River Clinic, Deer River
Essentia Health Cancer Center, Duluth
ja veel 8

VärbamineFaas 2

Vanused 18–59 · Kõik sood · Uuendatud 28. sept 2026 · NCT05554393

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Mercy Hospital, Coon Rapids
Essentia Health - Deer River Clinic, Deer River
Essentia Health Cancer Center, Duluth
ja veel 8

VärbamineFaas 2

Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. sept 2026 · NCT05564390

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

University of Minnesota/Masonic Cancer Center, Minneapolis

VärbamineFaas 1

Kuni 21 aastane · Kõik sood · Uuendatud 23. sept 2026 · NCT07012044

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Mercy Hospital, Coon Rapids
Essentia Health - Deer River Clinic, Deer River
Essentia Health Cancer Center, Duluth
ja veel 8

VärbamineFaas 2

Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. sept 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Mercy Hospital, Coon Rapids
Essentia Health - Deer River Clinic, Deer River
Essentia Health Cancer Center, Duluth
ja veel 8

VärbamineFaas 2

Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. sept 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Mercy Hospital, Coon Rapids
Essentia Health - Deer River Clinic, Deer River
Essentia Health Cancer Center, Duluth
ja veel 9

VärbamineFaas 2

Vanused 18–59 · Kõik sood · Uuendatud 22. sept 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
University of Minnesota/Masonic Cancer Center, Minneapolis
Mayo Clinic in Rochester, Rochester

VärbamineFaas 3

6 Months – 21 Years · Kõik sood · Uuendatud 17. sept 2026 · NCT04293562

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Mayo Clinic, Rochester

VärbamineFaas 1/2

Vanused 12 ja vanemad · Kõik sood · Uuendatud 3. sept 2026 · NCT04588922

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

US-Rochester MN-MAYOMN, Rochester

VärbamineFaas 3

Vanused 18 ja vanemad · Kõik sood · Uuendatud 2. sept 2026 · NCT06652438

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
University of Minnesota/Masonic Cancer Center, Minneapolis
Mayo Clinic in Rochester, Rochester

VärbamineFaas 1/2

Kuni 22 aastane · Kõik sood · Uuendatud 25. aug 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Masonic Cancer Center, Minneapolis

VärbamineFaas 3

29 Days – 21 Years · Kõik sood · Uuendatud 24. aug 2026 · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

University of Minnesota, Minneapolis

VärbamineFaas 3

Vanused 18 ja vanemad · Kõik sood · Uuendatud 20. aug 2026 · NCT07007312

Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

Masonic Cancer Center, Minneapolis

VärbamineFaas 1/2

Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. juuli 2026 · NCT07008638

HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

Masonic Cancer Center, Minneapolis

VärbamineFaas 1

Vanused 18 ja vanemad · Kõik sood · Uuendatud 14. juuli 2026 · NCT06594445

Allo HSCT Using RIC and PTCy for Hematological Diseases

Masonic Cancer Center at University of Minnesota, Minneapolis

VärbamineFaas 2

Kuni 75 aastane · Kõik sood · Uuendatud 6. juuli 2026 · NCT05805605

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Masonic Cancer Center at University of Minnesota, Minneapolis

VärbamineFaas 2

Kuni 60 aastane · Kõik sood · Uuendatud 25. juuni 2026 · NCT03314974

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Mayo Clinic in Rochester, Rochester

VärbamineFaas 1

Vanused 18 ja vanemad · Kõik sood · Uuendatud 10. juuni 2026 · NCT03017820

Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

Mark Juckett, MD, Minneapolis

VärbamineFaas 1/2

Vanused 18 ja vanemad · Kõik sood · Uuendatud 19. mai 2026 · NCT07591649

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

Masonic Cancer Center at University of Minnesota, Minneapolis

VärbamineFaas 2

Vanused 2–75 · Kõik sood · Uuendatud 16. apr 2026 · NCT07493538

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Mayo Clinic Comprehensive Cancer Center, Rochester

VärbamineFaas 1/2

Vanused 18 ja vanemad · Kõik sood · Uuendatud 13. apr 2026 · NCT05732103

Backtracking Leukemia-Typical Somatic Mutations in Cord Blood

University of Minnesota/Masonic Cancer Center, Minneapolis

VärbamineVaatlusuuring

Kuni 25 aastane · Kõik sood · Uuendatud 8. apr 2026 · NCT05014165

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

University of Minnesota Masonic Cancer Center, Minneapolis

VärbamineFaas 2

Kuni 60 aastane · Kõik sood · Uuendatud 6. apr 2026 · NCT05735717

Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy

Mayo Clinic in Rochester, Rochester

VärbamineVaatlusuuring

Vanused 18 ja vanemad · Kõik sood · Uuendatud 1. apr 2026 · NCT06279572

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

University of Minnesota, Minneapolis
Mayo Clinic - Rochester, Rochester

VärbamineFaas 1

Vanused 18 ja vanemad · Kõik sood · Uuendatud 13. märts 2026 · NCT05735184

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

Mayo Clinic, Rochester

VärbamineFaas 1

Vanused 18 ja vanemad · Kõik sood · Uuendatud 9. veebr 2026 · NCT06950034

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Mayo Clinic, Rochester

VärbamineTerved vabatahtlikud oodatud

Vanused 18–120 · Kõik sood · Uuendatud 25. juuli 2025 · NCT05237258

Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.